Leveraged & Inverse Channel Early IPO Activity Could Spell Bullishness for Biotech Industry By Ben HernandezJanuary 26, 2024
ETF Building Blocks Channel Biotech ETF SBIO’s Momentum Strong to End 2023 By Nick Peters-GoldenDecember 28, 2023
ETF Building Blocks Channel Play US Gene Treatment Approval in SBIO By Nick Peters-GoldenDecember 7, 2023
Leveraged & Inverse Channel 3 Trades to Consider Amid Early Summer Rally By Ben HernandezJuly 6, 2023
Beyond Basic Beta Channel Bull vs. Bear: How Healthy Are Biotech ETFs? By The VettaFi WritersMay 10, 2023
Disruptive Technology Channel Rising Biotech ETF HTEC Signaling a Buy By Nick Peters-GoldenMay 3, 2023
ETF Building Blocks Channel ALPS’ Biotech ETF SBIO Week’s Top Performer By Nick Peters-GoldenApril 24, 2023
ETF Building Blocks Channel Biotech ETFs’ Performance Deserves A Look By Nick Peters-GoldenApril 19, 2023
Disruptive Technology Channel Eye DNA Synthesis Advances in Active Biotech ETF ARKG By Nick Peters-GoldenFebruary 1, 2023
Disruptive Technology Channel EXAS Nears Key Buy Signal in Active Biotech ETF ARKG By Nick Peters-GoldenJanuary 11, 2023
Thematic Investing Channel Capture the Growth Potential in China’s Biotech Sector With This ETF By Ben HernandezDecember 27, 2022
Disruptive Technology Channel Biotech Earnings, Market Leap Boost ARKG Potential By Nick Peters-GoldenNovember 11, 2022
Leveraged & Inverse Channel Biotech Bounces in August as M&A Activity Increases By Ben HernandezAugust 22, 2022
Thematic Investing Channel Capitalize on Biotech Growth in China With This ETF By Ben HernandezJuly 21, 2022
Leveraged & Inverse Channel Biotech Belonged to the Bears in Second Half of 2021 By Ben HernandezDecember 25, 2021
Leveraged & Inverse Channel Omicron Variant Is Boosting This Leveraged Biotech ETF By Ben HernandezDecember 15, 2021
Nasdaq Investment Intelligence Channel How to Invest in Biotech in 2022 By Karrie GordonDecember 15, 2021